JUNTA TAKAMATSU, M.D.; MASAHIRO SUGAWARA, M.D.; KANJI KUMA, M.D.; AKIRA KOBAYASHI, M.D.; FUMIO MATSUZUKA, M.D.; TOSHIJI MOZAI, M.D.; JEROME M. HERSHMAN, M.D.
TAKAMATSU J, SUGAWARA M, KUMA K, KOBAYASHI A, MATSUZUKA F, MOZAI T, et al. Ratio of Serum Triiodothyronine to Thyroxine and the Prognosis of Triiodothyronine-Predominant Graves' Disease. Ann Intern Med. 1984;100:372-375. doi: 10.7326/0003-4819-100-3-372
Download citation file:
Published: Ann Intern Med. 1984;100(3):372-375.
Triiodothyronine (T3)-predominant Graves' disease is characterized by persistently high serum T3 level, normal serum thyroxine (T4) level, and high (> 20) serum T3/T4 ratio (nanograms/micrograms) during thionamide drug therapy. We studied the clinical course of 30 patients with T3-predominant Graves' disease. After receiving drug therapy for 1 to 4 years, 24 patients with T3-predominant Graves' disease had relapses, whereas only 9 control patients with Graves' disease whose serum T3/T4 ratio had become persistently normal (< 20) had relapses. The T3-predominant patients had greater serum TSH receptor antibody activity, thyroid T4 5′-deiodinase activity, and decreased T3 content of thyroglobulin when compared with the control patients. Our findings show that patients with T3-predominant Graves' disease are unlikely to have a long-term remission with drug therapy. The cause of high serum T3/T4 ratio is due, in part, to the more active thyroid T4 5′-deiodinase that may be mediated by high levels of Graves' immunoglobulin.
Learn more about subscription options.
Register Now for a free account.
Endocrine and Metabolism, Thyroid Disorders.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only